Title: The role of patient neuroimmune activation pathway genetics in pain and opioid response
Speaker: Dr Daniel Barratt, Clinical Pharmacogenetics and Drug Metabolism & Pharmacokinetics Laboratories, Discipline of Pharmacology, University of Adelaide
Biography: Dr Barratt completed his PhD at the University of Adelaide in 2010. Together with Prof Andrew Somogyi and Dr Janet Coller, he is a leader of the Clinical Pharmacogenomics and Drug Metabolism and Pharmacokinetics Laboratories of the Discipline of Pharmacology, and is a member of the Centre for Personalised Cancer Medicine, of the University of Adelaide. He is currently a NHMRC Postdoctoral Research Officer investigating personalised medicine for Aboriginal people with Prof Somogyi. He collaborates on international projects investigating the clinical pharmacogenetics of opioid pharmacokinetics, and the neuroimmune genetics of cancer pain, acute postoperative pain, and analgesia. In addition, he is leading research aimed at integrating clinical and experimental pharmacokinetics, pharmacogenomics and drug resistance markers, for the personalised dosing of tyrosine kinase inhibitors to fight cancer.
Chair: Dr John Licari, Clinical Pharmacology Unit TQEH, Level 2, BHI